SciGen Ltd., Singapore

SciGen Ltd. is a dynamic biopharmaceutical company dedicated to the development, manufacture, and marketing of recombinant human healthcare biotechnology-derived products. Focusing on endocrinology, oncology, and immunology, SciGen Ltd. is committed to improving patient outcomes through innovative and accessible biosimilar products. The company’s robust portfolio includes biosimilars such as recombinant human growth hormone, recombinant human insulin, recombinant human GCSF, recombinant human EPO, recombinant human interferon alfa, and a third-generation (mammalian cell culture-derived) hepatitis B vaccine. These products have undergone extensive clinical development and are in the process of securing health registration, ensuring their quality and efficacy.

SciGen Ltd.'s strategic approach centers on biosimilars (follow-on proteins) to mitigate the risks associated with early-stage product development. The company operates its own cutting-edge research and development center in Israel, concentrating on both bacteria (E. coli) and mammalian cell (CHO cell) technologies. This R&D center is dedicated to the continuous advancement of existing molecules and pursuing other innovative research activities. Through collaborations with strategic partners and institutions, SciGen Ltd. continually enhances and expands its product pipeline, driving future growth and innovation in the biopharmaceutical sector.

SciGen Ltd. is poised for continued success in the biotechnology industry. We invite the management team at SciGen Ltd. to create a customized and exclusive company showcase and product listing on our platform to further enhance your market presence and connect with a broader audience. This enhanced visibility will undoubtedly support SciGen Ltd.’s ongoing expansion and commercial objectives.